Roisin E. O'Cearbhaill, MD
Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.
“It’s important to remember that while we’re focusing on genetic testing, this shouldn’t delay us from starting treatment. It’s important that you have access to timely genetic testing,” said Roisin E. O'Cearbhaill, MD, during a presentation at the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma.
... to read the full story